Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial

R Thadhani, E Appelbaum, Y Pritchett, Y Chang… - Jama, 2012 - jamanetwork.com
Context Vitamin D is associated with decreased cardiovascular-related morbidity and
mortality, possibly by modifying cardiac structure and function, yet firm evidence for either …

Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease

H Tamez, C Zoccali, D Packham, J Wenger, I Bhan… - American heart …, 2012 - Elsevier
BACKGROUND: Left atrial enlargement, a sensitive integrator of left ventricular diastolic
function, is associated with increased cardiovascular morbidity and mortality. Vitamin D is …

Pooling mRNA in microarray experiments and its effect on power

W Zhang, A Carriquiry, D Nettleton… - Bioinformatics, 2007 - academic.oup.com
Motivation: Microarrays can simultaneously measure the expression levels of many genes
and are widely applied to study complex biological problems at the genetic level. To contain …

Efficacy and safety evaluation of HSD‐1 inhibitor ABT‐384 in Alzheimer's disease

GJ Marek, DA Katz, A Meier, N Greco IV… - Alzheimer's & …, 2014 - Wiley Online Library
Background In this study we assessed increased cortisol in Alzheimer's disease (AD)
patients. The selective 11‐β‐hydroxysteroid dehydrogenase type 1 (HSD‐1) inhibitor ABT …

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks …

RM Fleischmann, DF Alvarez, AE Bock… - RMD open, 2021 - rmdopen.bmj.com
Objective To investigate the efficacy, safety, immunogenicity and pharmacokinetics of
biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced …

[HTML][HTML] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference …

RM Fleischmann, DF Alvarez, AE Bock… - Arthritis research & …, 2021 - Springer
Abstract Background/objective REFLECTIONS B538–02 is a randomized, double-blind
comparative study of the adalimumab (ADL) biosimilar PF-06410293,(ADL-PF), and …

Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease

R Thadhani, E Appelbaum, Y Chang… - American journal of …, 2011 - karger.com
Background: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent
and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor …

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label …

RM Fleischmann, W Saikali, S Lakhanpal… - The Lancet …, 2023 - thelancet.com
Background An adalimumab biosimilar with an interchangeability designation could
increase access to effective treatment for more patients. We aimed to assess the …

Comparison of P aricalcitol With M axacalcitol Injection in J apanese Hemodialysis Patients With Secondary Hyperparathyroidism

T Akizawa, T Akiba, H Hirakata… - Therapeutic …, 2015 - Wiley Online Library
Secondary hyperparathyroidism (SHPT) is one of the major complications of chronic kidney
disease (CKD) and is associated with elevated serum intact parathyroid hormone (iPTH) …

The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease

Y Pritchett, Y Jemiai, Y Chang, I Bhan… - Clinical …, 2011 - journals.sagepub.com
Background Chronic kidney disease is associated with a marked increase in risk for left
ventricular hypertrophy and cardiovascular mortality compared with the general population …